Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. The COMPASS Trial. Circulation 2019; 140: 529-537
Published: 15th June 2020
Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al.
This study included over 27,000 patients with heart failure. Compared to aspirin alone, the combination of aspirin with twice-daily rivaroxaban reduced major adverse cardiovascular events: hazard ratio 0.68, 95 per cent confidence interval 0.53 to 0.86. Major adverse event rates were similar.Pubmed Link
You may also be interested in
No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a phase-III randomized-controlled trial. Ann Surg 2018; 268: 756-761.
Authors: Lindeman J, Zwaginga J, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ et al.
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg 2018; 67: 1922-1932.
Authors: Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS et al.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215-225.
Authors: Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al.
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387–399.
Authors: Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC et al.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229.
Authors: Anand S, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al.
Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2017; 12: e0175283.
Authors: Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA et al.
Evaluation of cell therapy on exercise performance and limb perfusion in peripheral artery disease. Circulation. 2017; 135: 1417-1428.
Authors: Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC et al.
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330.
Authors: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al.
Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease Fontaine stage IV: results of a placebo-controlled randomized multicenter trial (ESPECIAL). Eur J Vasc Endovasc Surg 2017; 53: 559-566.
Authors: Lawall H, Pokrovsky A, Checinski P, Ratushnyuk A, Hamm G, Randerath O et al.
Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. 10-year follow-up of a randomized controlled trial. Circulation. 2017; 135: 659-670.
Authors: Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M et al.
Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation. 2017; 135: 241-250.
Authors: Schuyler Jones W, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ et al.
Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017; 376: 1933-1942.
Authors: Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA et al.